Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 16054169 | HLA-DPB1*19 | beryllium disease | NA | NA | NA | unclassified | |
| among the 40 hla-dpb1 gene variants that code for e69, molecular epidemiological studies have suggested a risk hierarchy, where some variants appear to convey low to moderate risk of chronic beryllium disease (e.g., hla-dpb1*0201, approximately 3-fold increased risk), some convey an intermediate risk (e.g., hla-dpb1*1901, approximately 5-fold) and others convey high risk (e.g., hla-dpb1*1701, >10-fold). | |||||||
| 16054169 | HLA-DPB1*02 | beryllium disease | NA | NA | NA | unclassified | |
| among the 40 hla-dpb1 gene variants that code for e69, molecular epidemiological studies have suggested a risk hierarchy, where some variants appear to convey low to moderate risk of chronic beryllium disease (e.g., hla-dpb1*0201, approximately 3-fold increased risk), some convey an intermediate risk (e.g., hla-dpb1*1901, approximately 5-fold) and others convey high risk (e.g., hla-dpb1*1701, >10-fold). | |||||||
| 16607200 | HLA-DPB1 (HLA-DPB1) | beryllium disease | NA | NA | NA | unclassified | |
| under reasonable assumptions, the longitudinal positive predictive value of the hla-dpb1-glu69 marker of susceptibility to beryllium disease is 12%. | |||||||
| 17956852 | MHC (MHC) | beryllium disease | NA | NA | NA | negative | |
| impact of negatively charged patches on the surface of mhc class ii antigen-presenting proteins on risk of chronic beryllium disease. | |||||||
| 18317020 | HLA-DRB1 (HLA-DRB1) | beryllium disease | NA | NA | NA | unclassified | |
| in the absence of glu69, hla-drb1 alleles may function in beryllium presentation, increasing the risk of chronic beryllium disease. | |||||||
| 18479524 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | beryllium disease | NA | NA | NA | unclassified | |
| occupational exposure to beryllium may cause chronic beryllium disease (cbd), a lung disorder initiated by an electrostatic interaction with the mhc class ii human leukocyte antigen (hla). | |||||||
| 20356827 | HLA (HLA) | arginine | NA | guanidinium | NA | unclassified | |
| NA | |||||||
| 21186201 | HLA-DPB1 (HLA-DPB1) | beryllium disease | NA | NA | NA | unclassified | |
| our objective was to extend current knowledge of the genetics of beryllium disease by examining all hla-dpb1 and hla-dpr1 gene polymorphisms and the interactions between them. | |||||||
| 21460389 | HLA-DPA1 (HLA-DPA1) | beryllium disease | NA | NA | NA | unclassified | |
| sberyllium sensitisation (bes) and chronic beryllium disease (cbd) are caused by exposure to beryllium with susceptibility affected by at least one well-studied genetic host factor, a glutamic acid residue at position 69 (e69) of the hla-dpb chain (dpbe69). | |||||||
| 21471109 | HLA-DPB1 (HLA-DPB1) | beryllium disease | NA | NA | NA | unclassified | |
| risk of chronic beryllium disease by hla-dpb1 e69 genotype and beryllium exposure in nuclear workers. | |||||||
Copyright 2024